Partnering with Progenra
Building scientific alliances to advance mitochondrial disease therapies
Driving Innovation Through Collaboration
Progenra has a portfolio of novel Molecular Glue activators of PINK1 suitable for treating mitochondrial diseases such as PD, AD and Heart failure. We used our proprietary UbiProTM discovery platform to identify and characterize molecular glues. We seek partnership, funding and investment opportunities from both small and large institutions.
Leveraging UbiPro™ and UPS Expertise
Our unsurpassed know-how and expertise in the UPS, and portfolio of novel NCEs are paving the way for a new class of drug targeting mitochondrial diseases and aging.
Open to Licensing and Strategic Collaboration
Progenra is seeking industry partnerships for licensing opportunities of our PINK1 Molecular Glue portfolio.
Additionally, the Progenra Discovery Network, established through partnerships with CROs and academic experts, enhances Progenra’s development offerings to industry partners.
Molecular Glue Licensing
Redefining New Biology at the Intersection of Mitochondria and UPLS
Discovery Network (CROs + Academics)
Redefining New Biology at the Intersection of Mitochondria and UPLS
Strategic Development Partners
Redefining New Biology at the Intersection of Mitochondria and UPLS
Inviting Academic Research Collaborations
Progenra wishes to continue working with academic institutions to further dissect the ubiquitin proteasome system (UPS). In addition, Progenra encourages academic laboratories to contact us with potential collaborative projects. Progenra is especially interested in prospective collaborations with translational potential.
Inviting Academic Research Collaborations
We are pleased to have collaborations with several leading national and international academic institutions.
Let’s Partner for Scientific Breakthroughs
Please contact Progenra Business Development for inquiries:
